Video

Dr. Yu Discusses the Utility of GTx-758 in mCRPC

Author(s):

Evan Y. Yu, MD

In Partnership With:

Evan Y. Yu, MD, associate professor, Department of Medicine, Division of Oncology, University of Washington School of Medicine, Seattle Cancer Care Alliance, discusses the utility of GTx-758 in mCRPC.

Evan Y. Yu, MD, associate professor, Department of Medicine, Division of Oncology, University of Washington School of Medicine, Seattle Cancer Care Alliance, discusses the utility of GTx-758 in metastatic castration-resistant prostate cancer (mCRPC).

GTx-758 is a selective estrogen receptor alpha agonist that potentially has multiple mechanisms of action, including upregulating sex hormone binding globulin (SHBG) and lowering free testosterone levels.

In this trial, patients with mCRPC being treated with leuprorelin (Lupron) with low testosterone received low-dose (125 mg per day) GTx-758. These patients saw upregulated SHBG and decreased free testosterone levels, which translated into PSA declines. Researchers plan to analyze GTx-758 at 250 mg per day.

Related Videos
Christine M. Lovly, MD, PhD, Ingram Associate Professor of Cancer Research, associate professor, medicine (hematology/oncology), Vanderbilt-Ingram Cancer Center
Haeseong Park, MD, MPH
David L. Porter, MD
Timothy Yap, MBBS, PhD, FRCP
Leo I. Gordon, MD, Abby and John Friend Professor of Oncology Research, professor, medicine (hematology and oncology), Feinberg School of Medicine, Robert H. Lurie Cancer Center
Hetty E. Carraway, MD, MBA, staff associate professor, Department of Medicine, School of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; member, Immune Oncology Program, Case Comprehensive Cancer Center; vice chair, Strategy and Enterprise Development, Taussig Cancer Institute, Division of Hematologic Oncology and Blood Disorders, Cleveland Clinic
David A. Braun, MD, PhD, assistant professor, medicine (medical oncology), Louis Goodman and Alfred Gilman Yale Scholar, member, Center of Molecular and Cellular Oncology, Yale Cancer Center
Julia Foldi, MD, PhD
Vikram M. Narayan, MD
C. Ola Landgren, MD, PhD
Related Content
OncLive On Air
May 30th 2024

Revisit Every OncLive On Air Episode From May 2024

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Sarah ES Leary, MD, MS, of Fred Hutchinson
May 28th 2024

Tovorafenib Offers an Efficacious Option for R/R BRAF-Positive Pediatric Low-Grade Glioma

Hiba Khan, MD, MPH; Natasha Kwendakwema, MD
July 20th 2023

Khan and Kwendakwema Discuss Financial Toxicity in Patients With Cancer

FDA
May 28th 2024

FDA Approval Sought for Use of TLX007-CDx in PSMA PET Imaging of Prostate Cancer

Petros Grivas, MD, PhD, physician, Seattle Cancer Care Allliance; associate professor, Department of Medicine, Division of Oncology, clinical director, Genitourinary Cancers Program, University of Washington School of Medicine; associate member, Clinical Research Division, Fred Hutchinson Cancer Center
May 23rd 2024

Advances With Erdafitinib Exemplify the Push For Precision Medicine in Urothelial Cancer